# A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma

> **NCT01185548** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 4 (actual)

## Conditions studied

- Lymphoma
- Advanced Cancer

## Interventions

- **DRUG:** Tolbutamide
- **DRUG:** Tasisulam

## Key facts

- **NCT ID:** NCT01185548
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Terminated based on safety results from another trial
- **Last updated:** 2018-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01185548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01185548, "A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01185548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*